# Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)

> **NCT00048516** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 68 (—)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** paricalcitol capsule

## Key facts

- **NCT ID:** NCT00048516
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 68 (—)
- **Last updated:** 2006-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048516, "Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00048516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*